Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine

Bioorg Med Chem. 2011 Apr 15;19(8):2650-8. doi: 10.1016/j.bmc.2011.03.004. Epub 2011 Mar 10.

Abstract

Within our efforts in the discovery of novel potent and selective ligands for the FXR receptor, 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine was synthesized and evaluated for its ability to activate and modulate the biological response of the receptor. Alphascreen and RT-PCR revealed that the 6α-ethyl-24-norcholanyl-23-amine derivate behaves as full FXR agonist endowed with high binding affinity and efficacy, representing a promising lead candidate for further optimization. In addition, docking studies provide new insights into the molecular basis governing the partial and full agonist activity at FXR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bile Acids and Salts / chemistry*
  • Computer Simulation
  • Drug Discovery
  • Gastrointestinal Agents
  • Ligands
  • Protein Binding
  • Receptors, Cytoplasmic and Nuclear / agonists*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Structure-Activity Relationship

Substances

  • Bile Acids and Salts
  • Gastrointestinal Agents
  • Ligands
  • Receptors, Cytoplasmic and Nuclear
  • farnesoid X-activated receptor